Acadia Pharmaceuticals Inc (ACAD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acadia Pharmaceuticals Inc (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10071
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system disorders. The company’s lead product Nuplazid (pimavanserin) is an FDA approved drug for the treatment of Parkinson’s disease psychosis. Acadia also develops pimavanserin for the treatment of Alzheimer’s disease agitation and Alzheimer’s disease psychosis and as an adjunctive treatment for schizophrenia and major depressive disorder (MDD). The company has partnerships for the development of its drug candidates in the therapeutic areas of pain and ophthalmology. It has operational presence in Denmark and Switzerland. Acadia is headquartered in San Diego, California, the US.

Acadia Pharmaceuticals Inc (ACAD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ACADIA Pharma Enters into Licensing Agreement with Neuren Pharma 10
Equity Offering 11
Acadia Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD230 Million 11
Acadia Pharma Raises USD300 Million in Public Offering of Shares 13
Acadia Pharma Raises USD209.8 Million in Public Offering of Shares 15
Acadia Pharma Completes Public Offering Of Shares For US$115 Million 17
Acadia Pharma Completes Private Placement Of Shares And Warrants For US$84 Million 19
Acadia Pharmaceuticals Inc – Key Competitors 20
Acadia Pharmaceuticals Inc – Key Employees 21
Acadia Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 07, 2018: ACADIA Pharmaceuticals reports third quarter 2018 financial results 23
Aug 08, 2018: ACADIA Pharmaceuticals reports second quarter 2018 financial results 25
May 04, 2018: ACADIA Pharmaceuticals Announces First Quarter 2018 Financial Results 27
Feb 27, 2018: ACADIA Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 29
Nov 07, 2017: ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results 31
Aug 08, 2017: ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results 33
May 09, 2017: ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results 35
Feb 28, 2017: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 37
Corporate Communications 39
Sep 26, 2018: ACADIA Pharmaceuticals announces executive appointments 39
May 02, 2018: ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations 40
Dec 13, 2017: ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development 41
Mar 30, 2017: ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer 42
Legal and Regulatory 43
Jul 25, 2018: Federman & Sherwood announces filing of securities class action lawsuit against Acadia Pharmaceuticals 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acadia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ACADIA Pharma Enters into Licensing Agreement with Neuren Pharma 10
Acadia Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD230 Million 11
Acadia Pharma Raises USD300 Million in Public Offering of Shares 13
Acadia Pharma Raises USD209.8 Million in Public Offering of Shares 15
Acadia Pharma Completes Public Offering Of Shares For US$115 Million 17
Acadia Pharma Completes Private Placement Of Shares And Warrants For US$84 Million 19
Acadia Pharmaceuticals Inc, Key Competitors 20
Acadia Pharmaceuticals Inc, Key Employees 21
Acadia Pharmaceuticals Inc, Other Locations 22
Acadia Pharmaceuticals Inc, Subsidiaries 22

List of Figures
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Acadia Pharmaceuticals Inc (ACAD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Virgin Money PLC:企業の戦略的SWOT分析
    Virgin Money PLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • National Company KazMunayGas-石油・ガス分野:企業M&A・提携分析
    Summary National Company KazMunayGas (KazMunayGas) is a state-owned, vertically integrated oil and gas company. It carries out the acquisition, exploration, development, production, processing, transportation, refining and export of hydrocarbons. The company also produces petrochemicals, stores and …
  • AstraZeneca PLC:企業の戦略・SWOT・財務情報
    AstraZeneca PLC - Strategy, SWOT and Corporate Finance Report Summary AstraZeneca PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sparton Resources Inc (SRI):企業の財務・戦略的SWOT分析
    Summary Sparton Resources Inc (Sparton Resources) is a diversified company that acquires and develops oil and gas properties in North America and China. The company’s products portfolio includes vanadium, natural gas, crude oil, gold, and vanadium flow batteries, among others. Its energy projects co …
  • Powszechny Zaklad Ubezpieczen Group:戦略・SWOT・企業財務分析
    Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report Summary Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Sanochemia Pharmazeutika AG (SAC)-医療機器分野:企業M&A・提携分析
    Summary Sanochemia Pharmazeutika AG (Sanochemia) is a specialty pharmaceutical company that develops and manufactures of innovative drugs in selected indication areas such as neurodegeneration, pain and cancer, as well as diagnostic products based on contrast media. The company’s product portfolio i …
  • Tat Seng Packaging Group Ltd. (T12):企業の戦略的SWOT分析
    Tat Seng Packaging Group Ltd. (T12) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Zygo Corporation:企業の戦略的SWOT分析
    Zygo Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Sobeys Inc:戦略・SWOT・企業財務分析
    Sobeys Inc - Strategy, SWOT and Corporate Finance Report Summary Sobeys Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • PMA Companies Inc:企業の戦略・SWOT・財務分析
    PMA Companies Inc - Strategy, SWOT and Corporate Finance Report Summary PMA Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • AVX Corporation (AVX):企業の財務・戦略的SWOT分析
    AVX Corporation (AVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Generex Biotechnology Corp (GNBT):企業の戦略的SWOT分析
    Generex Biotechnology Corp (GNBT) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Polar Power Inc (POLA):企業の財務・戦略的SWOT分析
    Polar Power Inc (POLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • OnKure Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OnKure Inc (OnKure) is a drug developer that discovers and develops epigenetic therapies for the treatment of cancer. The company offers production of specific histone deacetylases inhibitors. Its lead product candidate ONK102 significantly reduces the growth rate of tumors in hematological …
  • AnGes Inc (4563):企業の財務・戦略的SWOT分析
    AnGes Inc (4563) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vitabiotics Ltd:企業の戦略的SWOT分析
    Vitabiotics Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Banco BPI SA:企業の戦略・SWOT・財務分析
    Banco BPI SA - Strategy, SWOT and Corporate Finance Report Summary Banco BPI SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • FibroGen Inc (FGEN):企業の財務・戦略的SWOT分析
    FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Tosoh Corp (4042):企業の財務・戦略的SWOT分析
    Tosoh Corp (4042) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Telekom Malaysia Bhd (TM):企業の財務・戦略的SWOT分析
    Telekom Malaysia Bhd (TM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆